Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

Journal of Infectious Diseases

Volumn 218, Issue , 2018, Pages S612-S626

  Pascal, Kristen E ^a   Dudgeon, Drew ^a   Trefry, John C ^b   Anantpadma, Manu ^c   Sakurai, Yasuteru ^c   Murin, Charles D ^d   Turner, Hannah L ^d   Fairhurst, Jeanette ^a   Torres, Marcela ^a   Rafique, Ashique ^a   Yan, Ying ^a   Badithe, Ashok ^a   Yu, Kevin ^a   Potocky, Terra ^a   Bixler, Sandra L ^b   Chance, Taylor B ^b   Pratt, William D ^b   Rossi, Franco D ^b   Shamblin, Joshua D ^b   Wollen, Suzanne E ^b   Zelko, Justine M ^b   Carrion, Ricardo ^b   Worwa, Gabriella ^c   Staples, Hilary M ^c   Burakov, Darya ^c   Babb, Robert ^a   Chen, Gang ^a   Martin, Joel ^a   Huang, Tammy T ^a   Erlandson, Karl ^a   Willis, Melissa S ^e   Armstrong, Kimberly ^e   Dreier, Thomas M ^e   Ward, Andrew B ^d   Davey, Robert A ^c   Pitt, Margaret L M ^b   Lipsich, Leah ^a   Mason, Peter ^a   Olson, William ^a   Stahl, Neil ^a   Kyratsous, Christos A ^a   more..

^a REGENERON PHARMACEUTICALS INC   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

EBOV; filovirus; monoclonal antibodies; treatment.

Indexed keywords

FC GAMMA RECEPTOR IIIA; FC RECEPTOR; GLYCOPROTEIN; HUMAN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ISOLATION; ANTIGEN BINDING; BINDING AFFINITY; CONFERENCE PAPER; CONTROLLED STUDY; DISSOCIATION; EBOLA HEMORRHAGIC FEVER; ELECTRON MICROSCOPY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIMATE; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS TITRATION; ZAIRE EBOLAVIRUS; ANIMAL; GUINEA PIG; HEK293 CELL LINE; IMMUNOLOGY; ISOLATION AND PURIFICATION; RHESUS MONKEY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; GLYCOPROTEINS; GUINEA PIGS; HEK293 CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA MULATTA; MALE; MICE;

EID: 85057165662     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy285     Document Type: Conference Paper

References (42)

1. Rougeron V, Feldmann H, Grard G, Becker S, Leroy EM. Ebola and Marburg haemorrhagic fever. J Clin Virol 2015; 64:111-9.
2. Tiffany A, Vetter P, Mattia J, et al. Ebola virus disease complications as experienced by survivors in Sierra Leone. Clin Infect Dis 2016; 62:1360-66.
3. Epstein L, Wong KK, Kallen AJ, Uyeki TM. Post-Ebola signs and symptoms in U. S. survivors. N Engl J Med 2015; 373:2484-6.
4. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 1996; 93:3602-7.
5. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 1998; 95:5762-7.
6. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008; 454:177-82.
7. Carette JE, Raaben M, Wong AC, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011; 477:340-3.
8. de La Vega MA, Wong G, Kobinger GP, Qiu X. The multiple roles of sGP in Ebola pathogenesis. Viral Immunol 2015; 28:3-9.
9. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011; 204(Suppl 3):S1075-81.
10. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 2013; 110:1893-8.
11. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386:857-66.
12. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.
13. Corti D, Misasi J, Mulangu S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 2016; 351:1339-42.
14. Bornholdt ZA, Turner HL, Murin CD, et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 2016; 351:1078-83.
15. Qiu X, Fernando L, Melito PL, et al. Ebola GP-specific monoclonal antibodies protect mice and Guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 2012; 6:e1575.
16. Olinger GG Jr, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 2012; 109:18030-5.
17. Pettit DK, Rogers RS, Arthur K, et al. CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody. MAbs 2016; 8:347-57.
18. Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014; 111:5147-52.
19. Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014; 111:5153-8.
20. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371:1418-25.
21. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in Guinea pigs. J Infect Dis 1999; 179(Suppl 1):S203-17.
22. Pascal KE, Coleman CM, Mujica AO, et al. Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A 2015; 112:8738-43.
23. Suloway C, Pulokas J, Fellmann D, et al. Automated molecular microscopy: The new Leginon system. J Struct Biol 2005; 151:41-60.
24. Lander GC, Stagg SM, Voss NR, et al. Appion: An integrated, database-driven pipeline to facilitate EM image processing. J Struct Biol 2009; 166:95-102.
25. Voss NR, Yoshioka CK, Radermacher M, Potter CS, Carragher B. DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J Struct Biol 2009; 166:205-13.
26. de la Rosa-Trevin JM, Oton J, Marabini R, et al. Xmipp 3. 0: An improved software suite for image processing in electron microscopy. J Struct Biol 2013; 184:321-8.
27. van Heel M, Harauz G, Orlova EV, Schmidt R, Schatz M. A new generation of the IMAGIC image processing system. J Struct Biol 1996; 116:17-24.
28. Yang Z, Fang J, Chittuluru J, Asturias FJ, Penczek PA. Iterative stable alignment and clustering of 2D transmission electron microscope images. Structure 2012; 20:237-47.
29. Tang G, Peng L, Baldwin PR, et al. EMAN2: An extensible image processing suite for electron microscopy. J Struct Biol 2007; 157:38-46.
30. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera-A visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605-12.
31. Murin CD, Fusco ML, Bornholdt ZA, et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A 2014; 111:17182-7.
32. Trefry JC, Wollen SE, Nasar F, et al. Ebola virus infections in nonhuman primates are temporally influenced by glycoprotein Poly-U editing site populations in the exposure material. Viruses 2015; 7:6739-54.
33. Jae LT, Brummelkamp TR. Emerging intracellular receptors for hemorrhagic fever viruses. Trends Microbiol 2015; 23:392-400.
34. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008; 112:2390-9.
35. Zeitlin L, Pettitt J, Scully C, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A 2011; 108:20690-4.
36. Kolokoltsov AA, Wang E, Colpitts TM, Weaver SC, Davey RA. Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. Am J Trop Med Hyg 2006; 75:702-9.
37. Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. Front Microbiol 2013; 4:267.
38. Mendoza EJ, Qiu X, Kobinger GP. Progression of Ebola therapeutics during the 2014-2015 outbreak. Trends Mol Med 2016; 22:164-73.
39. Misasi J, Gilman MS, Kanekiyo M, et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 2016; 351:1343-6.
40. Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000; 287:1664-6.
41. Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012; 4:138ra81.
42. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002; 76:6408-12.